复星医药：FXS887片获临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration for clinical trials of FXS887 for advanced malignant solid tumors, indicating a significant step in the company's oncology pipeline [1] Group 1: Clinical Development - The company plans to conduct Phase I clinical trials for FXS887 in China once conditions are met [1] - As of October 2025, the cumulative R&D investment for FXS887 is approximately RMB 44 million [1] - No other small molecule inhibitors targeting the same pathway have been approved globally for monotherapy or combination therapy [1]